Bio-Path Holdings Files 8-K: Material Agreement
Ticker: BPTH · Form: 8-K · Filed: Apr 4, 2024 · CIK: 1133818
| Field | Detail |
|---|---|
| Company | Bio-Path Holdings Inc (BPTH) |
| Form Type | 8-K |
| Filed Date | Apr 4, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001, $2,000,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, 8-k
TL;DR
Bio-Path Holdings just filed an 8-K for a material agreement - big news incoming.
AI Summary
On April 4, 2024, Bio-Path Holdings, Inc. filed an 8-K report detailing a material definitive agreement. The filing also includes financial statements and exhibits, indicating ongoing business operations and potential strategic moves.
Why It Matters
This filing signals a significant development for Bio-Path Holdings, Inc., potentially involving new partnerships, acquisitions, or financing that could impact its future operations and stock value.
Risk Assessment
Risk Level: medium — Material definitive agreements can introduce significant opportunities or risks depending on their nature and terms.
Key Players & Entities
- Bio-Path Holdings, Inc. (company) — Registrant
- April 4, 2024 (date) — Date of earliest event reported
FAQ
What is the nature of the material definitive agreement filed by Bio-Path Holdings, Inc.?
The filing indicates the entry into a material definitive agreement, but the specific details of the agreement are not provided in the summary information.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on April 4, 2024.
What is Bio-Path Holdings, Inc.'s principal executive office address?
The principal executive offices are located at 4710 Bellaire Boulevard, Suite 210, Bellaire, Texas 77401.
What is Bio-Path Holdings, Inc.'s telephone number?
The registrant's telephone number is (832) 742-1357.
What was Bio-Path Holdings, Inc.'s former company name?
The former company name was OGDEN GOLF CO CORP, with a date of name change on February 5, 2001.
Filing Stats: 855 words · 3 min read · ~3 pages · Grade level 10.3 · Accepted 2024-04-04 16:35:15
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share BPTH The Nasdaq Capital M
- $2,000,000 — or an aggregate offering price of up to $2,000,000. The foregoing summary of the ATM Agre
Filing Documents
- tm2411049d2_8k.htm (8-K) — 30KB
- tm2411049d2_ex5-1.htm (EX-5.1) — 8KB
- tm2411049d2_ex10-1.htm (EX-10.1) — 227KB
- tm2411049d2_ex5-1img001.jpg (GRAPHIC) — 30KB
- 0001104659-24-043661.txt ( ) — 533KB
- bpth-20240404.xsd (EX-101.SCH) — 3KB
- bpth-20240404_lab.xml (EX-101.LAB) — 33KB
- bpth-20240404_pre.xml (EX-101.PRE) — 22KB
- tm2411049d2_8k_htm.xml (XML) — 4KB
01 Entry into a Material Definitive
Item 1.01 Entry into a Material Definitive Agreement. On April 4, 2024, Bio-Path Holdings, Inc. (the "Company") entered into an At The Market Offering Agreement (the "ATM Agreement") with H.C. Wainwright & Co., LLC, ("Wainwright"), as sales agent, pursuant to which the Company may offer and sell, from time to time, through Wainwright shares of its common stock, $0.001 par value per share. The Company is not obligated to sell any shares under the ATM Agreement. Subject to the terms and conditions of the ATM Agreement, Wainwright will use commercially reasonable efforts consistent with its normal trading and sales practices, applicable state and federal law, rules and regulations and the rules of the Nasdaq Capital Market to sell shares from time to time based upon the Company's instructions, including any price, time or size limits specified by the Company. Under the ATM Agreement, Wainwright may sell shares by any method deemed to be an "at the market" offering as defined in Rule 415 under the U.S. Securities Act of 1933, as amended, or any other method permitted by law, including in privately negotiated transactions. The Company or Wainwright may suspend or terminate the offering of shares upon notice to the other party and subject to other conditions. The Company will pay Wainwright a commission equal to 3.0% of the aggregate gross proceeds from each sale of shares and has agreed to provide Wainwright with customary indemnification and contribution rights. The Company has also agreed to reimburse Wainwright for certain specified expenses. Sales of shares of common stock under the ATM Agreement will be made pursuant to the registration statement on Form S-3 (File No. 333-265282), which was declared effective by the U.S. Securities and Exchange Commission (the "SEC") on June 14, 2022, and a related prospectus supplement filed with the SEC on April 4, 2024, for an aggregate offering price of up to $2,000,000. The foregoing summary of the ATM Agreement does not p
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits . Exhibit Number Description 5.1 Opinion of Winstead PC 10.1 At The Market Offering Agreement, by and between Bio-Path Holdings, Inc. and H.C. Wainwright & Co., LLC, dated April 4, 2024 23.1 Consent of Winstead PC (included in Exhibit 5.1) 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIO-PATH HOLDINGS, INC. Dated: April 4, 2024 By: /s/ Peter H. Nielsen Peter H. Nielsen President and Chief Executive Officer